title: Hodgkin's disease: complications of therapy and excess mortality.
abstract: BACKGROUND
  The long-term survival of patients treated for Hodgkin's disease permits careful evaluation of long-term complications and excess mortality.
  
  
  METHODS
  Between 1960 and 1995, 2498 patients who were treated for Hodgkin's disease at Stanford University were evaluated. Survival, freedom from relapse, and important complications of therapy (cardiac disease and secondary cancers) were analyzed, and risk of mortality from all causes was calculated utilizing absolute excess risk calculations.
  
  
  RESULTS
  The risk of death from Hodgkin's disease is 17% at 15 years of follow-up and increases only slightly thereafter. The risk of death from other causes is also 17% at 15 years, but increases sharply thereafter. The major causes of mortality (other than Hodgkin's disease) are secondary cancers and cardiac disease. Second cancers with significant increase in risk include leukemia (acute nonlymphocytic), non-Hodgkin's lymphoma, lung/pleural cancer, breast cancer, melanoma, soft tissue and bone sarcomas, stomach cancer, salivary gland tumors, thyroid cancer, and pancreatic cancer. The absolute excess risk of death from causes other than Hodgkin's disease increases during each five-year follow-up interval for at least 25 years. However, the absolute excess risk of death during similar follow-up periods is less for patients treated in more recent years (1980-1995) than in the prior treatment era (1962-1980).
  
  
  CONCLUSIONS
  Mortality for causes other than Hodgkin's disease is important in the long-term follow-up of patients. Causes of death are often treatment related. Changes in treatment programs can reduce the long-term excess risk of death from complications of therapy.
authors.affiliation: Department of Radiation Oncology, Stanford University, School of Medicine, CA, USA.
authors.forename: R T
authors.initials: RT
authors.lastname: Hoppe
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006331:Heart Diseases / Q000209:etiology; D006689:Hodgkin Disease / Q000150:complications* / Q000401:mortality* / Q000628:therapy; D006801:Humans; D009364:Neoplasm Recurrence, Local; D016609:Neoplasms, Second Primary / Q000209:etiology*; D011878:Radiotherapy / Q000009:adverse effects; D012307:Risk Factors